Freenome
259 East Grand Avenue
Suite 3424
South San Francisco
California
94080
United States
Website: http://www.freenome.com/
About Freenome
Freenome (free•nohm) is the dynamic collection of genetic material floating in your blood (cell-free) derived from the trillions of cells in your body. It is your living cell-free genome changing over time and space.
YEAR FOUNDED:
2014
LEADERSHIP:
Founder and CEO: Gabriel Otte
Founder and COO: Riley Ennis
CTO: Michael Otte
CBO: Adam Drake
JOBS:
24 articles with Freenome
-
PREEMPT CRC™ Trial for Blood-Based Test to Detect Colon Cancer Has Expanded to Enroll Patients From Anywhere in the Continental U.S. During COVID-19 Pandemic
8/26/2020
COVID-19 pandemic has caused significant decline in colonoscopies and underscores the value of less invasive screening options for colorectal cancer (CRC)
-
Freenome Closes $270 Million Series C Financing to Advance Novel Multiomics Blood Testing Platform for Early Cancer Detection
8/26/2020
Proceeds will accelerate ongoing FDA registrational study of company’s first blood test for colorectal cancer screening and advance product pipeline
-
South San Francisco-based Freenome closed on an oversubscribed $270 million Series C financing.
-
Freenome Announces Initiation of the PREEMPT CRC Clinical Trial, a Registrational Study for the Early Detection and Prevention of Colorectal Cancer Using a Multiomics Blood Test
5/26/2020
Freenome , a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood draw, announced several new developments: initiating its PREEMPT CRC clinical trial; adding Gary Reedy, CEO of the American
-
ADC Therapeutics and Freenome Enter Biomarker Development Collaboration
8/26/2019
ADC Therapeutics to employ Freenome’s multiomics platform to identify biomarkers that correlate with clinical response to ADCT-402
-
Freenome Closes $160 Million Series B Financing to Advance Its Multiomics Blood Testing Platform for Early Cancer Detection
7/24/2019
Proceeds Will Fund Pivotal Validation Study of Company’s Blood-based Test for the Screening of Colorectal Cancer
-
Following additional study, Freenome said it plans to seek regulatory approval under the Parallel Review Program, the first application of its platform in colorectal cancer screening.
-
Freenome Bolsters Scientific Leadership, Naming Genomic-Medicine Pioneer, Jimmy Lin, As New Chief Scientific Officer
4/30/2019
Freenome, a leading artificial intelligence (AI) genomics company, today announced the appointment of Cheng-Ho Jimmy Lin, MD, PhD, MHS as Chief Scientific Officer (CSO).
-
Companies are filling in the gaps and the entire area of so-called “liquid biopsies” is hot these days, with companies like Guardant Health, Karius, Freenome, Apostle and GRAIL Bio entering the market. With this backdrop, let’s look at some companies working in the same field as the now-defunct T...
-
Readers' Picks: Top 10 Stories of 2018
12/28/2018
As we look back over the year, we noticed some stories just grabbed readers more than others. Here’s a look at the top 10 stories of the year, including job cuts, best-selling drugs, up-and-coming companies,scandals, clinical trials, and more. -
Freenome Unveils Promising Early Data on Colorectal Cancer Screening Test at American College of Gastroenterology Annual Meeting
10/9/2018
Freenome is presenting promising early data on its efforts to utilize machine learning to detect colorectal cancer (CRC) at its earliest stages, when treatment is most effective.
-
Investor Enthusiasm About Liquid Biopsies Drives Guardant Health IPO to $1.59 Billion Valuation
10/5/2018
Guardant Health went on the Nasdaq yesterday under the symbol GH. Shares climbed almost 70 percent on the first day of trading, selling 12.5 million shares at $19 per share in the initial public offering (IPO). -
Ilan Danieli, chief executive officer and co-founder of Precipio, a company with a liquid biopsy technology, took time to talk to BioSpace about the company and the economics of liquid biopsies.
-
Freenome’s IMPACT Advisory Board Brings Strategic Insight and Real-World Experience to AI-Genomics Cancer Tests
7/12/2018
Freenome announced the creation of its IMPACT Advisory Board, a group tasked with helping Freenome’s leadership team optimize the company’s short- and long-term strategies, including those for its first commercial launch.
-
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
-
QIAGEN showcases innovation in NGS solutions for precision medicine at ASCO 2018
5/31/2018
QIAGEN N.V. announced a partnership with Freenome, a leading artificial intelligence (AI) genomics company, to accelerate the development and commercialization of next-generation sequencing (NGS) tests to enable precision medicine in cancer treatment.
-
Freenome and Biognosys Announce Collaboration to Improve Early-Cancer Detection and Treatment
4/24/2018
Freenome’s platform is poised to detect cancer at its earliest stages and help clinicians optimize the next generation of precision therapies.
-
What You Need to Know About Freenome
1/8/2018
Freenome, headquartered in South San Francisco, is focused on developing a diagnostic test for early detection of cancer and other diseases on the so-called "liquid biopsy," in other words, blood. -
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
-
Invitae Chairman Randy Scott Joins Freenome Board of Directors
12/21/2017
For nearly three decades, Dr. Scott has been an entrepreneur and visionary leader in genomic medicine.